Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 308

1.

Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.

Genova C, Boccardo S, Mora M, Rijavec E, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Alama A, Vanni I, Barletta G, Bianchi R, Maggioni C, Bruzzi P, Grossi F.

J Clin Med. 2019 Oct 1;8(10). pii: E1566. doi: 10.3390/jcm8101566.

2.

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.

Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F, Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS, Francois CG.

Ophthalmology. 2019 Jul 16. pii: S0161-6420(18)33132-4. doi: 10.1016/j.ophtha.2019.07.011. [Epub ahead of print]

3.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
4.

Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.

Carbone F, Grossi F, Bonaventura A, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Biello F, Rossi G, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F.

Clin Exp Metastasis. 2019 Oct;36(5):449-456. doi: 10.1007/s10585-019-09984-z. Epub 2019 Aug 2.

PMID:
31376097
5.

Surgery or Locoregional Approaches for Hepatic Oligometastatic Pancreatic Cancer: Myth, Hope, or Reality?

Ghidini M, Petrillo A, Salati M, Khakoo S, Varricchio A, Tomasello G, Grossi F, Petrelli F.

Cancers (Basel). 2019 Aug 1;11(8). pii: E1095. doi: 10.3390/cancers11081095. Review.

6.

Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases.

Cortinovis D, Chiari R, Catino A, Grossi F, DE Marinis F, Sperandi F, Piantedosi F, Vitali M, Parra HJS, Migliorino MR, Tondini C, Tassinari D, Frassoldati A, Verderame F, Pazzola A, Cognetti F, Palmiotti G, Marchetti P, Santoro A, Giannarelli D, Colonese F, Delmonte A.

Anticancer Res. 2019 Aug;39(8):4265-4271. doi: 10.21873/anticanres.13590.

PMID:
31366516
7.

IoT-Based Home Monitoring: Supporting Practitioners' Assessment by Behavioral Analysis.

Mora N, Grossi F, Russo D, Barsocchi P, Hu R, Brunschwiler T, Michel B, Cocchi F, Montanari E, Nunziata S, Matrella G, Ciampolini P.

Sensors (Basel). 2019 Jul 23;19(14). pii: E3238. doi: 10.3390/s19143238.

8.

Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.

Bonaventura A, Grossi F, Carbone F, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Rossi G, Biello F, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F.

Cancer Immunol Immunother. 2019 Aug;68(8):1351-1358. doi: 10.1007/s00262-019-02367-z. Epub 2019 Jul 20.

PMID:
31327024
9.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.

PMID:
31319983
10.

Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial.

Santo A, Pilotto S, Galetta D, Grossi F, Fasola G, Romano G, Bonanno L, Bearz A, Papi M, Roca E, Catino A, Follador A, Rijavec E, Genova C, Petrillo P, Favaretto A, Giannone L, Milella M, Tortora G, Giannarelli D, Bria E; Italian association FONICAP (Operative National Interdisciplinary Force against Lung Cancer).

Lung Cancer. 2019 Aug;134:121-126. doi: 10.1016/j.lungcan.2019.06.011. Epub 2019 Jun 11.

PMID:
31319970
11.

Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab.

Alama A, Coco S, Genova C, Rossi G, Fontana V, Tagliamento M, Giovanna Dal Bello M, Rosa A, Boccardo S, Rijavec E, Biello F, Longo L, Cavalieri Z, Bruzzo C, Grossi F.

J Clin Med. 2019 Jul 10;8(7). pii: E1011. doi: 10.3390/jcm8071011.

12.

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.

Pesce S, Greppi M, Grossi F, Del Zotto G, Moretta L, Sivori S, Genova C, Marcenaro E.

Front Immunol. 2019 Jun 4;10:1242. doi: 10.3389/fimmu.2019.01242. eCollection 2019. Review.

13.

Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds.

Tagliamento M, Genova C, Rossi G, Coco S, Rijavec E, Dal Bello MG, Boccardo S, Grossi F, Alama A.

Expert Opin Investig Drugs. 2019 Jun;28(6):513-523. doi: 10.1080/13543784.2019.1627326. Epub 2019 Jun 7. Review.

PMID:
31159588
14.

Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus.

Tagliamento M, Grossi F, Paolino S, Rijavec E, Genova C, Rossi G, Biello F, De Maria A.

Immunotherapy. 2019 Jul;11(10):873-879. doi: 10.2217/imt-2019-0025. Epub 2019 Jun 3.

PMID:
31156006
15.

Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely.

Spallarossa P, Tini G, Sarocchi M, Arboscello E, Grossi F, Queirolo P, Zoppoli G, Ameri P.

J Clin Oncol. 2019 Sep 1;37(25):2201-2205. doi: 10.1200/JCO.18.02464. Epub 2019 May 14. No abstract available.

PMID:
31084547
16.

Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.

Dono M, De Luca G, Lastraioli S, Anselmi G, Dal Bello MG, Coco S, Vanni I, Grossi F, Vigani A, Genova C, Ferrarini M, Ravetti JL, Zupo S.

Mol Med. 2019 Apr 27;25(1):15. doi: 10.1186/s10020-019-0082-5.

17.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

Crinò L, Bidoli P, Delmonte A, Grossi F, De Marinis F, Ardizzoni A, Vitiello F, Lo Russo G, Parra HS, Cortesi E, Cappuzzo F, Calabrò L, Tiseo M, Turci D, Gamucci T, Antonelli P, Morabito A, Chella A, Giannarelli D, Galetta D.

Oncologist. 2019 Apr 17. pii: theoncologist.2018-0737. doi: 10.1634/theoncologist.2018-0737. [Epub ahead of print]

PMID:
30996007
18.

Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer.

Coco S, Bonfiglio S, Cittaro D, Vanni I, Mora M, Genova C, Dal Bello MG, Boccardo S, Alama A, Rijavec E, Sini C, Rossella V, Barletta G, Biello F, Truini A, Bruzzo C, Gallo M, Lazarevic D, Ballestrero A, Grossi F.

Cancers (Basel). 2019 Mar 28;11(4). pii: E441. doi: 10.3390/cancers11040441.

19.

Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.

Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, Baglivo S, Dal Bello MG, Ceribelli A, Grossi F, Chiari R.

Clin Lung Cancer. 2019 May;20(3):178-185.e2. doi: 10.1016/j.cllc.2019.02.001. Epub 2019 Feb 27.

PMID:
30910574
20.

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients.

Dal Bello MG, Filiberti RA, Alama A, Orengo AM, Mussap M, Coco S, Vanni I, Boccardo S, Rijavec E, Genova C, Biello F, Barletta G, Rossi G, Tagliamento M, Maggioni C, Grossi F.

J Transl Med. 2019 Mar 8;17(1):74. doi: 10.1186/s12967-019-1828-0.

21.

RETRACTED ARTICLE: Can baseline endocrinological examination and thyroid ultrasound predict the development of thyroid disease in immunotherapy-treated patients? Results from a prospective, single-center, open-label study.

Gay S, Rossi G, Corica G, Graziani G, Genova C, Rijavec E, Tagliamento M, Grossi F, Giusti M.

Endocrine. 2019 Mar 6. doi: 10.1007/s12020-019-01854-8. [Epub ahead of print]

PMID:
30840229
22.

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.

Crinò L, Bronte G, Bidoli P, Cravero P, Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, Grossi F, Tonini G, Sarobba MG, Pinotti G, Numico G, Samaritani R, Ciuffreda L, Frassoldati A, Bregni M, Santo A, Piantedosi F, Illiano A, De Marinis F, Tamberi S, Giannarelli D, Delmonte A.

Lung Cancer. 2019 Mar;129:35-40. doi: 10.1016/j.lungcan.2018.12.025. Epub 2019 Jan 15.

PMID:
30797489
23.

Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab.

Cusato J, Genova C, Tomasello C, Carrega P, Ottonello S, Pietra G, Mingari MC, Cossu I, Rijavec E, Leggieri A, Di Perri G, Dal Bello MG, Coco S, Boccardo S, Ferlazzo G, Grossi F, D'Avolio A.

Cancers (Basel). 2019 Jan 21;11(1). pii: E125. doi: 10.3390/cancers11010125.

24.

Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification.

Wang C, Xu F, Shen J, Zhang L, Zhang J, Jin J, Ampollini L, van Schil P, Kimura H, Grossi F, Suda K, Zhang B, Ma D; written on behalf of the AME Lung Cancer Collaborative Group.

J Thorac Dis. 2018 Nov;10(11):E779-E783. doi: 10.21037/jtd.2018.10.55. No abstract available.

25.

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.

Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R.

J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1.

PMID:
30506406
26.

Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.

Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, Grossi F.

Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062. doi: 10.1080/14656566.2018.1540591. Epub 2018 Nov 3. Review. Erratum in: Expert Opin Pharmacother. 2018 Dec;19(18):9.

PMID:
30392436
27.

The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer.

Rossi G, Alama A, Genova C, Rijavec E, Tagliamento M, Biello F, Coco S, Dal Bello MG, Boccardo S, Grossi F.

Expert Opin Pharmacother. 2018 Dec;19(17):1969-1976. doi: 10.1080/14656566.2018.1536746. Epub 2018 Oct 24. Review.

PMID:
30354693
28.

Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers.

Barbone F, Barbiero F, Belvedere O, Rosolen V, Giangreco M, Zanin T, Pisa FE, Meduri S, Follador A, Grossi F, Fasola G.

Int J Epidemiol. 2018 Dec 1;47(6):1981-1991. doi: 10.1093/ije/dyy212.

PMID:
30325420
29.

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.

Gridelli C, de Castro Carpeno J, Dingemans AC, Griesinger F, Grossi F, Langer C, Ohe Y, Syrigos K, Thatcher N, Das-Gupta A, Truman M, Donica M, Smoljanovic V, Bennouna J.

JAMA Oncol. 2018 Dec 1;4(12):e183486. doi: 10.1001/jamaoncol.2018.3486. Epub 2018 Dec 13. Erratum in: JAMA Oncol. 2018 Dec 1;4(12):1792.

30.

NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.

Gregorc V, Cavina R, Novello S, Grossi F, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A.

Oncologist. 2018 Oct;23(10):1133-e112. doi: 10.1634/theoncologist.2018-0292. Epub 2018 Aug 3.

31.

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F.

Eur J Cancer. 2018 Sep;100:126-134. doi: 10.1016/j.ejca.2018.05.015. Epub 2018 Jul 13.

PMID:
30014881
32.

Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy.

Gridelli C, Ascierto PA, Grossi F, Baldini E, Favaretto A, Garassino MC, Morabito A, Migliorino MR, Rossi A, de Marinis F.

Curr Clin Pharmacol. 2018;13(2):76-84. doi: 10.2174/1574884713666180711160008.

PMID:
29992894
33.

[Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.]

Fasola G, De Carlo E, Grossi F.

Recenti Prog Med. 2018 Jun;109(6):328-332. doi: 10.1701/2932.29487. Italian.

PMID:
29968861
34.

30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).

de Marinis F, Ciardiello F, Baas P, Crinò L, Giaccone G, Grossi F, Hellmann MD, Mok TSK, Lena H, Paz-Ares L, Rodriguez-Abreu D, Von Pavel J, Gridelli C.

ESMO Open. 2018 May 31;3(4):e000298. doi: 10.1136/esmoopen-2017-000298. eCollection 2018. Review.

35.

CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.

Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, Genova C.

Expert Opin Biol Ther. 2018 Jul;18(7):829-835. doi: 10.1080/14712598.2018.1492539. Epub 2018 Jul 4. Review.

PMID:
29936901
36.

NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.

Gregorc V, Gaafar RM, Favaretto A, Grossi F, Jassem J, Polychronis A, Bidoli P, Tiseo M, Shah R, Taylor P, Novello S, Muzio A, Bearz A, Greillier L, Fontana F, Salini G, Lambiase A, O'Brien M.

Lancet Oncol. 2018 Jun;19(6):799-811. doi: 10.1016/S1470-2045(18)30193-1. Epub 2018 May 9.

PMID:
29753703
37.

Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients.

Garassino MC, Gelibter AJ, Grossi F, Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L, Bengala C, Mini E, Baldini E, Quadrini S, Ceresoli GL, Antonelli P, Vasile E, Pinto C, Fasola G, Galetta D, Macerelli M, Giannarelli D, Lo Russo G, de Marinis F.

J Thorac Oncol. 2018 Aug;13(8):1146-1155. doi: 10.1016/j.jtho.2018.04.025. Epub 2018 May 3.

38.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.

N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.

39.

Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.

Sarocchi M, Grossi F, Arboscello E, Bellodi A, Genova C, Dal Bello MG, Rijavec E, Barletta G, Rossi G, Biello F, Ghigliotti G, Canepa M, Mussap M, Brunelli C, Spallarossa P.

Oncologist. 2018 Aug;23(8):936-942. doi: 10.1634/theoncologist.2017-0452. Epub 2018 Mar 22.

40.

Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy.

Grossi F, Genova C, Rijavec E, Barletta G, Biello F, Dal Bello MG, Meyer K, Roder J, Roder H, Grigorieva J.

Lung Cancer. 2018 Mar;117:64-69. doi: 10.1016/j.lungcan.2017.12.007. Epub 2017 Dec 13.

41.

Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects.

Spallarossa P, Meliota G, Brunelli C, Arboscello E, Ameri P, Dessalvi CC, Grossi F, Deidda M, Mele D, Sarocchi M, Bellodi A, Madonna R, Mercuro G.

Med Res Rev. 2018 Sep;38(5):1447-1468. doi: 10.1002/med.21478. Epub 2017 Dec 28. Review.

PMID:
29283446
42.

Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?

Genova C, Rijavec E, Grossi F.

J Thorac Dis. 2017 Nov;9(11):4300-4304. doi: 10.21037/jtd.2017.10.66. No abstract available.

43.

Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients with unresected malignant pleural mesothelioma.

Truini A, Coco S, Nadal E, Genova C, Mora M, Dal Bello MG, Vanni I, Alama A, Rijavec E, Biello F, Barletta G, Merlo DF, Valentino A, Ferro P, Ravetti GL, Stigliani S, Vigani A, Fedeli F, Beer DG, Roncella S, Grossi F.

Oncotarget. 2017 Aug 2;8(40):68627-68640. doi: 10.18632/oncotarget.19800. eCollection 2017 Sep 15.

45.

Understanding the checkpoint blockade in lung cancer immunotherapy.

Dal Bello MG, Alama A, Coco S, Vanni I, Grossi F.

Drug Discov Today. 2017 Aug;22(8):1266-1273. doi: 10.1016/j.drudis.2017.05.016. Epub 2017 Jun 7. Review.

PMID:
28600190
46.

Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.

Coco S, Alama A, Vanni I, Fontana V, Genova C, Dal Bello MG, Truini A, Rijavec E, Biello F, Sini C, Burrafato G, Maggioni C, Barletta G, Grossi F.

Int J Mol Sci. 2017 May 11;18(5). pii: E1035. doi: 10.3390/ijms18051035.

47.

Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: 18F-FDG PET/CT Study.

Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, Rijavec E, Bongioanni F, Biello F, Dal Bello MG, Barletta G, Massollo M, Vanni I, Piva R, Nieri A, Bauckneht M, Sambuceti G, Grossi F.

J Nucl Med. 2017 Nov;58(11):1764-1769. doi: 10.2967/jnumed.117.193201. Epub 2017 Apr 27.

48.

Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer.

Rijavec E, Genova C, Barletta G, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Vanni I, Boccardo S, Alama A, Grossi F.

Expert Opin Investig Drugs. 2017 May;26(5):551-561. doi: 10.1080/13543784.2017.1316714. Epub 2017 Apr 13. Review.

PMID:
28388262
49.

Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.

Genova C, Rossi G, Rijavec E, Biello F, Barletta G, Tagliamento M, Grossi F.

Expert Opin Drug Saf. 2017 May;16(5):573-585. doi: 10.1080/14740338.2017.1313228. Epub 2017 Apr 19. Review.

PMID:
28351171
50.

Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?

Bauckneht M, Piva R, Sambuceti G, Grossi F, Morbelli S.

World J Radiol. 2017 Feb 28;9(2):27-33. doi: 10.4329/wjr.v9.i2.27.

Supplemental Content

Loading ...
Support Center